A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)
Clinical trial NCT02614066 · COMPLETED
Trial details
- NCT number
- NCT02614066
- Sponsor
- Kite, A Gilead Company
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-03-07
- Primary completion
- 2022-07-23
- Enrollment
- 125
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.